Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-05175157 with Canagliflozin in T2DM
NCT02053116Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Mar 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PF-05175157 in type 2 diabetes mellitus (T2DM), sponsored by Pfizer. Started Mar 2014; status: terminated.
02
Drugs
PF-05175157
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02053116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02053116.